New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

UCLA researchers gave T cells a protected supply of sugar, allowing them to attack solid tumors more effectively.

Metabolism guides the activation states of regulatory T cells, the immune cells that prevent inappropriate activation of the immune system. St. Jude Children's Research Hospital scientists recently ...

Persistent viral infections pose a unique challenge to the immune system. Prolonged antigen exposure drives T cells into a state of exhaustion — a ...

Immunotherapy has transformed cancer care, offering a way to harness the body’s own immune system to fight tumors. But even with these advances, many patients still don’t respond. One major barrier to ...

Indiana University School of Medicine scientists have developed a new method that shifts the behavior of immunosuppressive cells in tumors, turning them from cancer protectors into tumor fighters.

Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized treatment for various blood cancers. When traditional treatments fail, CAR-T therapies provide a second highly effective option.

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...